Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595244 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
A Phase 3 study, sponsored by Point Biomedical.
- Completed
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT00595244 is a Phase 3 study that has completed, run by Point Biomedical. The registered enrollment target is 456 participants.
The verdict
NCT00595244, a Phase 3 study, has completed, sponsored by Point Biomedical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
This trial is to compare PB127 echocardiography to other heart imaging studies.
Interventions
- DRUG PB127 for injectable suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595244
The ClinicalTrials.gov registry entry for NCT00595244 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Point Biomedical, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PB127 for injectable suspension is the first listed.
NCT00595244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00595244 about?
NCT00595244 is a clinical study titled "Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease". This trial is to compare PB127 echocardiography to other heart imaging studies.
What is the current status of trial NCT00595244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2002-07. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00595244?
The interventions under investigation include: PB127 for injectable suspension (DRUG).
Who is sponsoring clinical trial NCT00595244?
This trial is sponsored by Point Biomedical, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.